(Q33384027)

English

Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consort

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consort (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

David C Smith

4

0 references

6

object named as

Tomasz M Beer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

object named as

Eric J Small

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Jonathan E Rosenberg

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Charles J Ryan

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vivian K Weinberg

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maha Hussain

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christopher W Ryan

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Paul Mathew

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lance C Pagliaro

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrea L Harzstark

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeremy Sharib

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

6 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2772-2778

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

21 June 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

21 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

21 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

21 June 2018

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

31 October 2018

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

31 October 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

31 October 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2698016

31 October 2018

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19349545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19349545

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.19.8002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33384027&oldid=2186406583"